Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Atrial fibrillation; Chronic heart failure; Hypertension; Myocardial infarction; Stroke
- Focus Therapeutic Use
- Acronyms PARALLEL-HF; SAVASAVA Study
- Sponsors Novartis Pharma KK; Novartis Pharmaceuticals
- 12 Nov 2023 Results of subgroup analysis, evaluating the efficacy and safety of sacubitril/valsartan according to baseline SBP tertiles in Japanese patients published in the Circulation Journal
- 26 Aug 2023 Results (n=115) of an open-label extension (OLE) of PARALLEL-HF study assessing long-term safety with sacubitril/valsartan published in the Circulation Journal
- 26 Mar 2021 Status changed from active, no longer recruiting to completed.